MarketCap
Facebook
X
Telegram
C4 Therapeutics Balance Sheet 2025-2011 | CCCC
Brief overview of C4 Therapeutics's balance sheet strength
This overview follows the five latest available annual observations between 2021 and 2025.
The asset base decreased -29.1%, from $506.8 million to $359.1 million. Resources became smaller over the five periods.
Asset growth of -29.1% came with a -12.5% rise in liabilities. Financial leverage became more prominent.
Equity funds 71.5% of assets versus 76.9% initially. This creates a conservative balance sheet structure.
Cash exceeds interest-bearing debt, producing net debt of -$14.6 million. The balance sheet therefore carries a net cash position.
Cash equals 20.8% of the balance sheet, compared with 15% five periods ago. This is the readily available cushion.
The balance sheet includes a negative accumulated result of -$738.7 million. It should be assessed alongside historical profits and capital distributions.
Overall picture
C4 Therapeutics's financial structure is not clear-cut. Asset scale alone does not resolve questions about how those assets are funded.
Annual Balance Sheet C4 Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-14.6 M | 10.3 M | -55.6 M | -15.9 M | -64 M | -171 M | -76.8 M | -21.8 M | - | - | - | - | - | - | - |
Long Term Debt |
53.6 M | 60 M | 65.8 M | 9.2 M | 10.8 M | 10.1 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
6.37 M | 5.77 M | 5.22 M | 4.7 M | 1.33 M | 1.04 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 75.5 M | 197 M | 202 M | - | - | - | - | - | - | - |
Total Current Liabilities |
33 M | 45.2 M | 42.8 M | 44.5 M | 51.2 M | 43.9 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
102 M | 134 M | 130 M | 142 M | 117 M | 119 M | 230 M | 226 M | - | - | - | - | - | - | - |
Deferred Revenue |
12.5 M | 18.7 M | 15.5 M | 16.6 M | 31.8 M | 27.6 M | 20.7 M | 19.1 M | - | - | - | - | - | - | - |
Retained Earnings |
-739 M | -634 M | -528 M | -396 M | -268 M | -184 M | -117 M | -83.4 M | - | - | - | - | - | - | - |
Total Assets |
359 M | 350 M | 376 M | 431 M | 507 M | 400 M | 118 M | 146 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
74.6 M | 55.5 M | 127 M | 29.8 M | 76.1 M | 182 M | 90.5 M | 38.9 M | - | - | - | - | - | - | - |
Book Value |
257 M | 216 M | 246 M | 289 M | 390 M | 281 M | -112 M | -79.8 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
257 M | 216 M | 246 M | 289 M | 390 M | 281 M | -112 M | -79.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet C4 Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
53.6 M | 51.9 M | 60 M | 55.2 M | 56.9 M | 58.4 M | 60 M | 61.5 M | 62.9 M | 64.4 M | 65.8 M | - | - | 8.62 M | 9.2 M | 9.05 M | - | 10.2 M | 10.8 M | 10.6 M | 10.4 M | 10.2 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 12.9 M | 12.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
102 M | 94.6 M | 134 M | 111 M | 122 M | 124 M | 134 M | 133 M | 134 M | 140 M | 130 M | 117 M | 141 M | 134 M | 142 M | 143 M | - | 151 M | 117 M | 109 M | 112 M | 110 M | 119 M | 119 M | 119 M | 119 M | 119 M | 119 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
12.5 M | 10.1 M | 18.7 M | 17.1 M | 22.6 M | 21.6 M | 18.7 M | 20.8 M | 36.6 M | 35.1 M | 15.5 M | 8.42 M | 14 M | 14.9 M | 16.6 M | 18.1 M | - | 31.3 M | 31.8 M | 32.3 M | 28.7 M | 26.6 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 20.7 M | 20.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-739 M | -764 M | -634 M | -718 M | -686 M | -660 M | -634 M | -599 M | -574 M | -557 M | -528 M | -494 M | -467 M | -431 M | -396 M | -359 M | - | -299 M | -268 M | -252 M | -227 M | -205 M | -184 M | -184 M | -184 M | -184 M | -117 M | -117 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
359 M | 329 M | 350 M | 265 M | 297 M | 320 M | 350 M | 376 M | 381 M | 398 M | 376 M | 333 M | 375 M | 396 M | 431 M | 461 M | - | 515 M | 507 M | 508 M | 528 M | 374 M | 400 M | 400 M | 400 M | 400 M | 118 M | 118 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
58.9 M | 61.3 M | 130 M | 58.8 M | 78.2 M | 51.3 M | 55.5 M | 59.6 M | 73.1 M | 89.7 M | 127 M | 61 M | 44.9 M | 49.5 M | 29.8 M | 49.6 M | 57.3 M | 46 M | 76.1 M | 163 M | 281 M | 94.9 M | 182 M | 182 M | 182 M | 182 M | 90.5 M | 90.5 M | - | - | 38.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
257 M | 234 M | 216 M | 154 M | 174 M | 195 M | 216 M | 243 M | 247 M | 258 M | 246 M | 216 M | 234 M | 262 M | 289 M | 318 M | - | 365 M | 390 M | 399 M | 416 M | 264 M | 281 M | 281 M | 281 M | 281 M | -968 K | -968 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
216 M | 234 M | 246 M | 154 M | 174 M | 195 M | 216 M | 243 M | 247 M | 258 M | 246 M | 216 M | 234 M | 262 M | 289 M | 318 M | 345 M | 365 M | 390 M | 399 M | 416 M | 264 M | 281 M | 281 M | 281 M | 281 M | -112 M | -112 M | -93.4 M | - | -79.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of C4 Therapeutics, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
USA
Canada
China
France
Germany
Israel
Britain
Russia
Belgium
Cayman-islands
